Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1444 • ACR Convergence 2022
Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
YENFU CHEN and Yao-Fan Fang, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Patients with systemic lupus erythematosus (SLE) had a higher risk of pericarditis, which could be life-threating, but there has been no research focusing on…
Abstract Number: 1461 • ACR Convergence 2022
The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis
Omer Pamuk¹ and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus…
Abstract Number: 1480 • ACR Convergence 2022
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Clarice P. Lin¹ and Richard C. Chou², ¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, ²University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY
Background/Purpose: Kidney disease is a common manifestation of systemic lupus erythematosus (SLE); when it presents as glomerulonephritis also known as lupus nephritis (LN), it predicts…
Abstract Number: 1654 • ACR Convergence 2022
Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
Jacquelyn Nestor¹, Christian Mancini¹, Baijun Zhou¹, Yuqing Zhang², Karen Costenbader³, Hyon Choi⁴ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is the backbone of SLE therapy, due to its benefits on increasing survival and decreasing lupus flares. In 2011, ophthalmology guidelines recommended…
Abstract Number: 1717 • ACR Convergence 2022
Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli
Afroditi Boulougoura¹, Hao Li¹, Rhea Bhargava¹, Wenliang Pan¹, Abhigyan Satyam¹, Isaac Stillman² and George Tsokos¹, ¹Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Interleukin 23 (IL-23) is involved in the pathogenesis of systemic lupus erythematosus (SLE). IL-23 is elevated in the sera of patients with active SLE…
Abstract Number: 2020 • ACR Convergence 2022
Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
Anna Nagel¹, Bhuwan Khatri¹, Marcin Radziszewski¹, Mandi Wiley¹, Anna Stolarczyk¹, Michelle Joachims¹, Kandice Tessneer¹, Astrid Rasmussen¹, Professor Simon Bowman², Lida Radfar³, Roald Omdal⁴, Marie Wahren-Herlenius⁵, Blake Warner⁶, Torsten Witte⁷, Roland Jonsson⁸, Maureen Rischmueller⁹, Patrick Gaffney¹, Judith James¹, Lars Ronnblom¹⁰, Hal Scofield¹, Xavier Mariette¹¹, Marta Alarcon-Riquelme¹², Fai Ng¹³, Gunnel Nordmark¹⁰, Qing Sun¹⁴, Kwangwoo Kim¹⁵, Sang-Cheol Bae¹⁶, Betty Tsao¹⁴, A. Darise Farris¹ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University Hospitals Birmingham, Birmingham, United Kingdom, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Stavanger University, Stavanger, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Institutes of Health, Bethesda, MD, ⁷MH-Hannover, Hannover, Germany, ⁸University of Bergen, Bergen, Norway, ⁹RheumatologySA, Adelaide, Australia, ¹⁰Uppsala University, Uppsala, Sweden, ¹¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Kyung Hee University, Seoul, Republic of Korea, ¹⁶Hanyang University Medical Center, Seoul, Republic of Korea
Background/Purpose: Dysregulated autophagy is implicated in systemic lupus erythematous (SLE) and Sjögren's disease (SjD), including dysregulated expression of Autophagy-related gene 5 (ATG5) and Autophagy Related…
Abstract Number: 2067 • ACR Convergence 2022
Predictors of Organ Damage Accrual by Domains
Rangi Kandane-Rathnayake¹, Ning Li¹, Vera Golder¹, Worawit Louthrenoo², Yi-Hsin Chen³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Luo Shue Fen⁷, Yeong-Jian Wu⁷, Sandra Navarra⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, An Yuan¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Yanjie Hao¹⁴, Zhouli Zhang¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Shereen Oon¹⁹, Sang-Cheol Bae²⁰, Fiona Goldblatt²¹, Sean O'Neill²², Kathy Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Duminda Basnayake²⁵, Nicole Tugnet²⁶, Sunil Kumar²⁷, Cherica Tee²⁸, Michael Tee²⁸, Yoshiya Tanaka²⁹, Chak Sing³⁰, Mandana Nikpour³¹, Alberta Hoi³² and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Chiang Mai University, Chiang Mai, Thailand, ³Taichung Veterans General Hospital, Taichung, Taiwan, ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰People's Hospital, Peking University Health Science Center, Beijing, China, ¹¹Peking University Health Science Center, Beijing, China, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁴The University of Melbourne, Melbourne, Australia, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹St Vincent's Hospital, Fitzroy, Australia, ²⁰Hanyang University Medical Center, Seoul, Republic of Korea, ²¹Flinders Medical Centre, Adelaide, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ²⁶Greenlane Clinical Centre, Auckland, New Zealand, ²⁷Middlemore Hospital, Auckland, New Zealand, ²⁸University of the Philippines, Quezon City, Philippines, ²⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³⁰The University of Hong Kong, Pok Fu Lam, Hong Kong, ³¹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³²Monash Health, Melbourne, Australia, ³³Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Prevention of organ damage is one of the main treatment goals in systemic lupus erythematosus (SLE).The SLICC/ACR Damage Index (SDI) is used to quantify…
Abstract Number: 2085 • ACR Convergence 2022
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of osteoporosis on major adverse cardiovascular events (MACEs) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus…
Abstract Number: 2105 • ACR Convergence 2022
Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
Alexandra Legge¹, Sarah Lieber² and John Hanly³, ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Frailty is associated with increased risk of adverse health outcomes in SLE. Multiple definitions for frailty exist, and how best to measure frailty in…
Abstract Number: 2266 • ACR Convergence 2022
Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis
Marc Scherlinger¹, Pierre Vacher², Vivien Guillotin³, Isabelle Douchet⁴, Christophe Richez⁵ and Patrick Blanco⁴, ¹BIDMC Harvard University, Boston, MA, ²INSERM U1218, Bordeaux, France, ³CHU de Bordeaux, Bordeaux, France, ⁴UMR-CNRS 5164 Immunoconcept, Bordeaux, France, ⁵CHRU Bordeaux, Bordeaux, France
Background/Purpose: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown…
Abstract Number: 0082 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
Jean Park, W. Cliff Rutter, Will Cavers, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…
Abstract Number: 0221 • ACR Convergence 2022
Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education
Katie Robinson¹, Jillian Scavone¹, William Cioffi¹, Robert Esgro¹ and Leonard Calabrese², ¹Vindico Medical Education, Thorofare, NJ, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Given the recent advances in the management of patients systemic lupus erythematosus (SLE), rheumatology and primary care providers are challenged to administer the latest…
Abstract Number: 0334 • ACR Convergence 2022
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
Zara Izadi¹, Alfredo Aguirre², Christine Anastasiou², Julia Kay³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵UCSF, San Rafael, CA
Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…
Abstract Number: 0351 • ACR Convergence 2022
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
Yasuhiro Hasegawa¹, Yoshiyuki Arinuma², Yu Matsueda¹, Kenji Oku³ and Kunihiro Yamaoka⁴, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Kitasato University, Kanagawa, Japan, ³Kitasato University, Chigasaki, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].